Coming Down the Pike: Endocannabinoids - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Coming Down the Pike: Endocannabinoids
Scientists are uncovering signaling systems that operate via cannabinoid messenger molecules.


Pharmaceutical Technology


Dorling Kindersley/Getty Images
Anyone who lived through the '60s and remembers it undoubtedly had some experience—direct or otherwise—of tetrahydrocannabinol, the active ingredient in marijuana. The drug produces what many consider to be pleasant effects on the nervous system, the likely reason for its popularity. And that led to two general conclusions. The first was that the drug mimicked some chemicals that could be made and found within the human body, and second, that these endogenous cannabinoids would most likely be found in the brain.

After many years of research, scientists are in fact uncovering signaling systems that operate via cannabinoid messenger molecules. But much to their surprise, the collection of receptors and endogenous cannabinoids (endocannabinoids) are found more diffusely throughout the body.

In a review article in Nature Reviews Drug Discovery, Vincenzo Di Marzo, a member of the Endocannabinoid Research Group at the Institute of Biomolecular Chemistry, National Research Council in Naples, Italy, recounts the number of pathologies in which endocannabinoids have been associated and, presumably in which cannabinoids may offer some therapeutic benefits. These include pain and inflammation, immunological (autoimmune and allergic) disorders, neurological and neuropsychiatric conditions, obesity, metabolic, and cardiovascular disorders, cancer, and disorders of the gastrointestinal track as well as the liver.

The diversity of physiological systems and conditions regulated by endocannabinoids opens up a tremendous number of potential novel therapeutic interventions for a variety of diseases. At the same time, it opens up the possibility that each cannabinoid-based therapeutic will have a tremendous number of side effects.

In conclusion, says the author, "for those who are engaged in developing new therapeutics by targeting the endocannabinoid system, this task can be described by Giuseppe Verdi's definition (in La Traviata) of love as 'Croce e Delizia': a series of painstaking, and sometimes frustrating, efforts alternating with immense gratifications."

Source: V. Di Marzo, "Targeting the Endocannabinoid System: To Enhance or Reduce?" Nature Rev. Drug Disc. 7 (5), 438–455 (2008).

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here